Applied DNA Sciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James A. Hayward Sc.D.
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 50 Health Sciences Drive Stony Brook NY United States of America 11790
- IPO Date
- Jul 15, 2003
- CIK
- 0000744452
- Website
- adnas.com
- Similar Companies
- Business
- Applied DNA Sciences, Inc. Applied DNA Sciences, Inc. (NASDAQ:APDN) is a biotechnology company specializing in polymerase chain reaction (PCR)-based DNA technologies for the production and detection of DNA, primarily through its majority-owned subsidiary LineaRx Inc.; core products and services encompass the LineaDNA platform, a cell-free system producing high-fidelity linear DNA free of adventitious sequences for mRNA production, gene and cell therapy, vaccines, diagnostics, and nucleic acid-based therapeutics from 100 base pairs to 20 kilobases in milligram-to-gram quantities under RUO, GLP, and GMP grades; the integrated LineaIVT platform combining LineaDNA with proprietary LineaRNAP enzyme for streamlined mRNA workflows that reduce double-stranded RNA contamination; and previously offered DNA tagging solutions such as SigNature DNA for supply chain security, anti-counterfeiting, and molecular authentication in textiles, pharmaceuticals, and agriculture, alongside molecular diagnostics and genetic testing via Applied DNA Clinical Labs. Founded in 1983 and headquartered in Stony Brook, New York, the company operates principally in the United States with a strategic focus on biopharma, research institutions, IVD manufacturers, and global pharmaceutical firms developing CAR T therapies and cancer diagnostics. Recent developments include a June 2025 strategic restructuring to concentrate exclusively on synthetic DNA manufacturing via LineaRx, featuring a 27% workforce reduction, cessation of Applied DNA Clinical Labs operations effective June 27, 2025, and exit from the DNA tagging and security segment in February 2025 to cut costs by approximately 31% in annual payroll; partnerships such as a March 2024 scale-up agreement with Alphazyme LLC for LineaRNAP production and a November 2024 evaluation deal with a top-20 global pharmaceutical company for LineaDNA in CAR therapy manufacturing; follow-on orders for LineaDNA in cancer diagnostics from a global IVD firm in July and September 2025; leadership transition with the June 2025 retirement of former Chairman and CEO Dr. James A. Hayward; and a shift announced in October 2025 to a new ticker BNBX with initiation of a digital asset treasury strategy involving up to $58 million private placement for BNB holdings and yield generation, alongside Nasdaq compliance restoration in July 2025.
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress